Keytruda 100mg/4ml Injection Wholesale USA: Ernest Impex – Verified India Exporter

Keytruda 100mg/4ml Injection – Leading Immunotherapy | Global Bulk Supply by Ernest Impex

Keytruda 100mg/4ml (Pembrolizumab) is a revolutionary anti-PD-1 therapy that has redefined the standard of care in oncology. As of 2026, its applications continue to expand across multiple solid tumors and hematological malignancies. Ernest Impex (Group of Ernest Pharmaceutical Pvt. Ltd.), a premier pharmaceutical exporter from India, ensures the seamless distribution and specialized cold-chain logistics for Keytruda 100 mg/4 ml to Washington (USA), London (UK), Canberra (Australia), Bangkok (Thailand), Kingston (Jamaica), and Singapore.

Comprehensive Product Information: Keytruda 100mg/4ml

1. Advanced Formulation & Classification

• Active Ingredient: Pembrolizumab (25 mg/mL).

• Total Content: 100 mg in a 4 mL single-dose vial.

• Drug Class: Programmed Death Receptor-1 (PD-1) Blocking Antibody.

• Mechanism of Action: Keytruda is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2). By inhibiting this "checkpoint," it reactivates the body's immune T-cells, allowing them to detect and destroy cancer cells that were previously "hiding" from the immune system.

2. 2026 Therapeutic Indications & FDA Approvals

Keytruda is indicated for an extensive range of cancers, with recent 2026 approvals expanding its reach:

• Melanoma: Adjuvant treatment for Stage IIB, IIC, or III melanoma following complete resection.

• Non-Small Cell Lung Cancer (NSCLC): First-line treatment (monotherapy or combination) for metastatic NSCLC expressing PD-L1 (TPS ≥1%).

• Renal Cell Carcinoma (RCC): Adjuvant treatment for patients at high risk of recurrence following nephrectomy.

• Urothelial Carcinoma: In combination with Padcev (enfortumab vedotin) for locally advanced or metastatic bladder cancer.

• Ovarian Cancer: Recent 2026 approvals include combinations for platinum-resistant epithelial ovarian and fallopian tube carcinomas.

• MSI-H/dMMR Solid Tumors: For adult and pediatric patients with unresectable or metastatic solid tumors that have progressed following prior treatment.

3. Administration & Dosage Protocol

• Standard Dose: Typically 200 mg every 3 weeks or 400 mg every 6 weeks for adult patients.

• Administration: Delivered as an intravenous (IV) infusion over 30 minutes.

• Preparation: Must be diluted in 0.9% sodium chloride or 5% dextrose injection.

4. Safety Profile & Monitoring

• Immune-Mediated Adverse Reactions (imARs): Because Keytruda activates the immune system, it can cause the body to attack healthy organs. Serious reactions can occur in the lungs (pneumonitis), intestines (colitis), liver (hepatitis), and endocrine glands (thyroiditis).

• Common Side Effects: Fatigue, musculoskeletal pain, rash, diarrhea, and nausea.

• Cold-Chain Storage: Must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light.